Resources
68 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 1/26/2024 (updated 3/28/2024)
Posted 10/12/2023 (updated 3/27/2024)
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 7/26/2023 (updated 3/28/2024)
Just 5 years ago, only 1% of jails and prisons provided MOUD, but this practice has flourished. Dr. Costello discussed the emerging evidence base for MOUD in jails, regulatory changes, funding opportunities, and the dramatic increase in usage of MOUD in our nation's correctional facilities.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 7/26/2023 (updated 3/26/2024)
Given the smaller size of our cohort, our goal was to create an opportunity for personal interactions, in-person peer-to-peer discussion, and facilitated peer-to-peer learning.
Posted 7/21/2023 (updated 3/28/2024)
Disparities in access to naloxone exist and organizations are working to remove some of these barriers by utilizing innovative methods such as vending machines to distribute the overdose medication. This provides life-saving medication in an accessible way to everyone, although laws vary state to state on the distribution of these tools. More information on naloxone vending machines can be found in these resources by the Bureau of Justice Assistance's (BJA) Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) and The Network for Public Health Law.
Posted 4/4/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration (FDA) announced that the makers of Narcan, an opioid overdose treatment, have the agency’s approval to make the drug widely available over the counter (OTC). Narcan is the brand name of the drug naloxone, a fast-acting overdose reversal. Until now, availability varied by state – typically restricted to licensed health care providers, approved opioid overdose programs, and first responders. This is an important consideration for rural counties given that research shows that these areas are nearly three times more likely than metropolitan counties to be a low-dispensing county for naloxone.
Posted 11/1/2022 (updated 3/27/2024)
Racial/ethnic minorities have experienced disproportionate opioid-related overdose death rates in recent years. In this context, inequities were examined in community-based naloxone access across racial/ethnic groups in Massachusetts.
Posted 10/3/2022 (updated 3/27/2024)
The United States overdose crisis continues unabated. Despite efforts to increase capacity for treating opioid use disorder (OUD) in the U.S., how actual treatment receipt compares to need remains unclear. In this cross-sectional study, progress is estimated in addressing the gap between OUD prevalence and OUD treatment receipt at the national and state levels from 2010 to 2019.